



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,

12.11.2024

Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

Dear Sir,

Sub: Outcome Of Board Meeting

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Tuesday, 12th November, 2024**, at the office of company, have inter-alia-

1. Approved the Standalone and Consolidated Unaudited Financial Results and Limited Review Report for the quarter and half year ended on 30th September, 2024.

In terms of the Provisions of Regulation 33 and of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Unaudited Financial Results for the quarter and half year ended on ended 30th September, 2024.
2. Limited Review Report for the quarter and half year ended on ended 30th September, 2024.

The meeting of Board of Directors commenced at **03:00 P.M. and concluded at 03:40 P.M.**

The above information will be available on the website of the Company i.e <https://titanbiotechltd.com>

This is for your kind information and record please.

Thanking You,

For Titan Biotech Limited

Charanjit Singh
Company Secretary & Compliance Officer
M. No A12726



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and year to date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Titan Biotech Limited (the "Company"), for the quarter ended September 30, 2024 and the year to date results for the period 1st April 2024 to 30 September 2024 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Report" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

**AKHIL
MITTAL**



(CA Akhil Mittal)

Partner

M.No. 517856

Date: 12.11.2024

Place: New Delhi

UDIN: 24517856BKHCFG4281



A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and Year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Titan Biotech Limited (the "Company") and its Associates, for the quarter ended September 30, 2024 and the consolidated year to date results for the period from 1 April 2024 to 30 September 2024 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Report" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2024

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	INCOME						
	Revenue from operations	3,989.11	4,311.46	4,342.71	8,300.57	7,817.45	16,407.21
	Other Income	31.86	62.37	55.21	94.23	83.40	174.82
	Total Income	4,020.97	4,373.83	4,397.92	8,394.80	7,900.85	16,582.03
2	EXPENSES						
	Cost of Materials Consumed	1,619.24	2,234.58	2,044.78	3,853.82	3,936.34	8,089.24
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	131.86	(57.87)	77.42	73.99	(357.54)	(528.63)
	Employee Benefits Expense	649.90	627.06	546.57	1,276.96	1,088.34	2,371.06
	Finance Costs	26.55	30.90	27.99	57.45	56.55	117.00
	Depreciation and Amortization Expense	109.64	104.73	85.98	214.37	165.58	333.06
	Other Expenses	812.09	682.73	802.58	1,494.82	1,490.21	3,047.40
	Total Expenses	3,349.28	3,622.13	3,585.32	6,971.41	6,379.48	13,429.13
3	Profit before exceptional items and tax (1-2)	671.69	751.70	812.60	1,423.39	1,521.37	3,152.90
4	Exceptional Items	-	-	-	-	-	-
5	Profit before tax (3+4)	671.69	751.70	812.60	1,423.39	1,521.37	3,152.90
6	Tax expense:						
	(I) Current Tax	162.95	181.73	209.90	344.68	377.30	778.87
	(II) Deferred Tax	8.09	0.01	2.38	8.10	3.12	10.61
	(III) Earlier year taxes	0.30	-	(2.59)	0.30	(2.90)	(2.90)
	Total Tax (I+II+III)	171.34	181.74	209.69	353.08	377.52	786.58
7	Profit for the period (5-6)	500.35	569.96	602.91	1,070.31	1,143.85	2,366.32
8	Other comprehensive income						
A.	(i) Items that will not be reclassified to profit or loss						
	(ia) Re-measurement gain on defined benefit plans	5.84	5.84	2.08	11.68	4.16	23.36
	(ii) Income tax relating to these items	(1.47)	(1.47)	(0.52)	(2.94)	(1.05)	(5.88)
B.	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to these items	-	-	-	-	-	-
	Total Other Comprehensive Income for the period (A+B) (net of taxes)	4.37	4.37	1.56	8.74	3.11	17.48
9	Total Comprehensive Income for the period (7+8)	504.72	574.33	604.47	1,079.05	1,146.96	2,383.80
10	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
11	Other Equity						12,017.85
12	Earnings per equity share (face value of Rs.10/- each) not annualised						
	(1) Basic	6.05	6.90	7.30	12.95	13.84	28.64
	(2) Diluted	6.05	6.90	7.30	12.95	13.84	28.64

Notes:

- The above standalone unaudited financial results for the quarter and six months ended on 30.09.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on November 12, 2024. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter and six months ended on 30th Sept. 2024, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30th Sept. 2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

[Naresh Kumar Singla]
Managing Director
DIN-00027448



Place : Delhi
Dated : 12.11.2024

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RHICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2024

(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	Total Income from Operations (Net)	4,020.97	4,373.83	4,397.92	8,394.80	7,900.85	16,582.03
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	671.69	751.70	812.60	1,423.39	1,521.37	3,152.90
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	671.69	751.70	812.60	1,423.39	1,521.37	3,152.90
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	500.35	569.96	602.91	1,070.31	1,143.85	2,366.32
5	Total comprehensive income for the period (comprising Profit for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	504.72	574.33	604.47	1,079.05	1,146.96	2,383.80
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	12,017.85
8	Earnings Per Share (of INR 10/- each)						
	(a) Basic	6.05	6.90	7.30	12.95	13.84	28.64
	(b) Diluted	6.05	6.90	7.30	12.95	13.84	28.64

NOTES :

- The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter and six months ended on 30.09.2024 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter and six months ended on 30.09.2024 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above standalone unaudited financial results for the quarter and six months ended on 30.09.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on November 12, 2024. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30.09.2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

[Naresh Kumar Singla
Managing Director
DIN-00027448



Place : Delhi
Dated : 12.11.2024


TITAN BIOTECH LIMITED
Standalone Balance Sheet as at 30th September, 2024

(Rs. in Lakhs.)

Particulars	As at	
	30/09/2024 Unaudited	31/03/2024 Audited
I ASSETS		
I. Non-Current Assets		
a. Property, Plant and Equipment	4,697.62	4,262.55
b. Capital Work-in-Progress	226.88	253.21
c. Right of use Assets	996.18	931.21
d. Intangible assets	6.12	7.22
e. Intangible assets under development	2.99	2.28
f. Financial Assets		
(i) Investments	1,157.84	2,318.33
(ii) Other Financial Assets	342.53	164.87
Total Non-current assets	7,430.16	7,939.67
2. Current Assets		
a. Inventories	4,928.89	4,557.10
b. Financial Assets		
(i) Trade receivables	2,404.47	1,865.79
(ii) Cash and cash equivalents	805.61	284.01
(iii) Bank balances other than (ii) above	197.43	-
c. Current Tax Assets (Net)	-	5.28
d. Other Current Assets	803.27	505.23
Total Current assets	9,139.67	7,217.41
TOTAL ASSETS	16,569.83	15,157.08
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	12,931.63	12,017.84
TOTAL EQUITY	13,758.00	12,844.21
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	70.62	45.33
(ii) Lease liabilities	140.47	69.44
b. Deferred tax liabilities (Net)	148.28	137.24
c. Provisions	150.45	148.34
Total Non-Current Liabilities	509.82	400.35
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	9.69	671.76
(ii) Lease liabilities	40.53	43.76
(iii) Trade payables		
(a) Total outstanding dues of micro enterprise and small enterprises	102.84	55.65
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	664.93	281.17
(iv) Other financial liabilities	750.81	565.73
b. Other current liabilities	620.52	238.81
c. Provisions	55.64	55.64
d. Current Tax Liabilities (Net)	57.05	-
Total Current Liabilities	2,302.01	1,912.52
TOTAL EQUITY AND LIABILITIES	16,569.83	15,157.08

For Titan Biotech Limited


 [Naresh Kumar Singla]
 Managing Director
 DIN-00027448



Place : Delhi
Date : 12.11.2024

TITAN BIOTECH LIMITED

Standalone Cash Flow Statement for the period ended on 30th September, 2024

(Rs. in Lakhs.)


Particulars	Six months ended	Six months ended
	30/09/2024	30/09/2023
	Unaudited	Unaudited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	1,423.39	1,521.37
Adjustment for :		
Finance Costs	57.45	56.55
Provisions	13.79	17.25
Earlier year Taxes	(0.30)	2.90
Unrealised foreign exchange differences	(2.03)	-
Depreciation and Amortization Expenses	214.37	165.58
Operating profit before working capital changes	1,706.67	1,763.65
Changes in working Capital:		
(Increase) in Inventories	(371.79)	(616.52)
(Increase)/ Decrease in Trade Receivables	(538.69)	(283.72)
(Increase)/ Decrease in Other Financial Assets	(177.66)	(15.47)
Decrease in Other Current Assets	(296.06)	174.31
Increase/ (Decrease) in Trade Payables	431.02	(68.42)
Increase/ (Decrease) in Other Financial Liabilities	185.08	(8.32)
Increase/ (Decrease) in Other Current Liabilities	381.71	184.69
Cash generation from Operation	1,320.28	1,130.20
Payment of Direct Taxes	(282.35)	(302.74)
Net Cash generated/ (used) - Operating Activities	1,037.93	827.46
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Investment in equity shares	1,160.49	(68.35)
Purchase of Property, Plant and Equipment	(608.98)	(956.79)
Proceeds from Sale of Property, Plant & Equipment	1.23	0.40
Addition of Capital Work in Progress (Net)	26.33	384.06
Purchase of Intangible assets under development	(0.70)	-
(Addition) in Right of use assets	(105.56)	(16.80)
Proceeds From/(Investment in) bank deposits	(197.43)	-
Net Cash Generated/ (Used) - Investing Activities	275.38	(657.48)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	25.29	88.07
Repayment of Lease Liabilities	67.80	(19.05)
Proceeds/(Repayment) of Short-term Borrowings (Net)	(662.07)	(63.70)
Finance Cost paid	(57.46)	(56.55)
Dividend paid	(165.27)	(148.74)
Net Cash Generated/ (Used) - Financing Activities	(791.71)	(199.97)
Net Increase/ (Decrease) in Cash and Cash Equivalents	521.60	(29.99)
Add : Opening Cash and Cash Equivalents	284.01	486.37
Closing Cash and Cash Equivalents	805.61	456.38

Notes:

- The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
- Figures in bracket represent outflows.
- Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For Titan Biotech Limited

[Naresh Kumar Singla
Managing Director
DIN-00027448



Place : Delhi
Date : 12.11.2024

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2024

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED	
1	INCOME						
	Revenue from operations	3,989.11	4,311.46	4,342.71	8,300.57	7,817.45	16,407.21
	Other Income	31.86	62.37	55.21	94.23	83.40	174.82
	Total Income	4,020.97	4,373.83	4,397.92	8,394.80	7,900.85	16,582.03
2	EXPENSES						
	Cost of Materials Consumed	1,619.24	2,234.58	2,044.78	3,853.82	3,936.34	8,089.24
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	131.86	(57.87)	77.42	73.99	(357.54)	(528.63)
	Employee Benefit Expense	649.90	627.06	546.57	1,276.96	1,088.34	2,371.06
	Finance Costs	26.55	30.90	27.99	57.45	56.55	117.00
	Depreciation and Amortization Expense	109.64	104.73	85.98	214.37	165.58	333.06
	Other Expenses	812.09	682.73	802.58	1,494.82	1,490.21	3,047.40
	Total Expenses	3,349.28	3,622.13	3,585.32	6,971.41	6,379.48	13,429.13
3	Profit before exceptional items and tax (1-2)	671.69	751.70	812.60	1,423.39	1,521.37	3,152.90
4	Exceptional Items	-	-	-	-	-	-
5	Profit before tax (3+4)	671.69	751.70	812.60	1,423.39	1,521.37	3,152.90
6	Tax expense:						
	(I) Current Tax	162.95	181.73	209.90	344.68	377.30	778.87
	(III) Deferred Tax	8.09	0.01	2.38	8.10	3.12	10.61
	(II) Earlier year taxes	0.30	-	(2.59)	0.30	(2.90)	(2.90)
	Total Tax (I+II+III)	171.34	181.74	209.69	353.08	377.52	786.58
7	Profit for the period (5-6)	500.35	569.96	602.91	1,070.31	1,143.85	2,366.32
8	Share in Profit of Associate	169.16	70.00	49.23	239.16	124.35	118.98
9	Profit for the period (7+8)	669.51	639.96	652.14	1,309.47	1,268.20	2,485.30
10	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss						
A	(ia) Re-measurement gain on defined benefit plans	5.84	5.84	2.08	11.68	4.16	23.36
	(ii) Income tax relating to these items	(1.47)	(1.47)	(0.52)	(2.94)	(1.05)	(5.88)
B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to these items	-	-	-	-	-	-
	Total Other Comprehensive Income for the period (A+B) (net of taxes)	4.37	4.37	1.56	8.74	3.11	17.48
11	Total Comprehensive Income for the period (7+8)	673.88	644.33	653.70	1,318.21	1,271.31	2,502.78
12	Net profit attributable to:						
	Owners of the holding company						
	Non-controlling interest						
13	Other comprehensive income attributable to:						
	Owners of the holding company						
	Non-controlling interest						
14	Total Comprehensive Income attributable to (10+11)						
	Owners of the holding company						
	Non-controlling interest						
15	Paid-up equity share capital (Face Value of Rs. 10/- each)	826.37	826.37	826.37	826.37	826.37	826.37
16	Other Equity						12,518.75
17	Earnings per equity share (face value of Rs. 10/- each) not annualised						
	(1) Basic	8.10	7.74	7.89	15.85	15.35	30.07
	(2) Diluted	8.10	7.74	7.89	15.85	15.35	30.07

Notes:

- The above consolidated unaudited financial results for the quarter and six months ended on 30.09.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on November 12, 2024. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter and six months ended Sept. 30, 2024, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- The consolidated unaudited financial results for the quarter and six months ended on 30.09.2024 include the results of following:-
Associate Companies - Peptech Biosciences Limited and Titan Media Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended Sept. 30, 2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

[Naresh Kumar Singla]
Managing Director
DIN-00027448



Place : Delhi
Dated :12.11.2024

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2024

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations (Net)	4,020.97	4,373.83	4,397.92	8,394.80	7,900.85	16,582.03
2	Net Profit for the period (before tax, exceptional and/or extraordinary items)	671.69	751.70	812.60	1,423.39	1,521.37	3,152.90
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	671.69	751.70	812.60	1,423.39	1,521.37	3,152.90
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	669.51	639.96	652.14	1,070.31	1,143.85	2,485.30
5	Total comprehensive income for the period (comprising Profit for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	673.88	644.33	653.70	1,318.21	1,271.31	2,502.78
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	-	-	12,518.75
8	Earnings Per Share (of INR 10/- each)						
	(a) Basic	8.10	7.74	7.89	15.85	15.35	30.07
	(b) Diluted	8.10	7.74	7.89	15.85	15.35	30.07

NOTES :

- The above is an extract of the detailed format of consolidated unaudited Financial Results for the quarter and six months ended on 30.09.2024 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter and six months ended on 30th Sept 2024 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.
- The above consolidated unaudited financial results for the quarter and six months ended on 30.09.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on November 12, 2024. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and six months ended on 30.09.2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

Place : Delhi
Dated :12.11.2024



For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED


(Signature)
[Naresh Kumar Singla]
Managing Director
DIN-00027448


TITAN BIOTECH LIMITED
Consolidated Balance Sheet as at 30th September, 2024

(Rs. in Lakhs.)

Particulars	As at	
	30/09/2024 Unaudited	31/03/2024 Audited
I ASSETS		
1. Non-Current Assets		
a. Property, Plant and Equipment	4,697.62	4,262.55
b. Capital Work-in-Progress	226.88	253.21
c. Right of use Assets	996.18	931.21
d. Intangible assets	6.12	7.22
e. Intangible assets under development	2.99	2.28
f. Financial Assets		
(i) Investments	1,897.90	2,819.24
(i) Other Financial Assets	342.53	164.87
Total Non-current assets	8,170.22	8,440.58
2. Current Assets		
a. Inventories	4,928.89	4,557.10
b. Financial Assets		
(i) Trade receivables	2,404.47	1,865.79
(ii) Cash and cash equivalents	805.61	284.01
(iii) Bank balances other than (ii) above	197.43	-
c. Current Tax Assets (Net)	-	5.28
d. Other Current Assets	803.27	505.23
Total Current assets	9,139.67	7,217.41
TOTAL ASSETS	17,309.89	15,657.99
II. EQUITY AND LIABILITIES		
A Equity		
a. Equity Share Capital	826.37	826.37
b. Other Equity	13,671.69	12,518.75
TOTAL EQUITY	14,498.06	13,345.12
B Liabilities		
1. Non-Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	70.62	45.33
(ii) Lease liabilities	140.47	69.44
b. Deferred tax liabilities (Net)	148.28	137.24
c. Provisions	150.45	148.34
Total Non-Current Liabilities	509.82	400.35
2. Current Liabilities		
a. Financial Liabilities		
(i) Borrowings	9.69	671.76
(ii) Lease liabilities	40.53	43.76
(iii) Trade payables		
(a) Total outstanding dues of micro enterprise and small enterprises	102.84	55.65
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	664.93	281.17
(iv) Other Financial Liabilities	750.81	565.73
b. Other current liabilities	620.52	238.81
c. Provisions	55.64	55.64
d. Current Tax Liabilities (Net)	57.05	-
Total Current Liabilities	2,302.01	1,912.52
TOTAL EQUITY AND LIABILITIES	17,309.89	15,657.99

For Titan Biotech Limited


 [Naresh Kumar Singla]
 Managing Director
 DIN-00027448



Place : Delhi
Date : 12.11.2024

TITAN BIOTECH LIMITED

Consolidated Cash Flow Statement for the period ended on 30th September, 2024


(Rs. in Lakhs.)


Particulars	Six months ended	Six months ended
	30/09/2024	30/09/2023
	Unaudited	Unaudited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before Tax	1,423.39	1,521.37
Adjustment for :		
Finance Costs	57.45	56.55
Earlier year Taxes	(0.30)	17.25
Provision for employees Benefits	13.79	2.90
Unrealised foreign exchange differences	(2.03)	-
Depreciation and Amortization Expenses	214.37	165.58
Operating profit before working capital changes	1,706.67	1,763.65
Changes in working Capital:		
(Increase) in Inventories	(371.79)	(616.52)
(Increase)/ Decrease in Trade Receivables	(538.69)	(283.72)
(Increase)/ Decrease in Other Financial Assets	(177.66)	(15.47)
Decrease in Other Current Assets	(296.06)	174.31
Increase/ (Decrease) in Trade Payables	431.02	(68.42)
Increase/ (Decrease) in Other Financial Liabilities	185.08	(8.32)
Increase/ (Decrease) in Other Current Liabilities	381.71	184.69
Cash generation from Operation	1,320.28	1,130.20
Payment of Direct Taxes	(282.35)	(302.74)
Net Cash generated/ (used) - Operating Activities	1,037.93	827.46
B. CASH FLOW FROM INVESTMENT ACTIVITIES		
Investment in equity shares	1,160.49	(68.35)
Purchase of Property, Plant and Equipment	(608.98)	(956.79)
Proceeds from Sale of Property, Plant & Equipment	1.23	0.40
Addition of Capital Work in Progress (Net)	26.33	384.06
Purchase of Intangible assets under development	(0.70)	-
(Addition) in Right of use assets	(105.56)	(16.80)
Proceeds From/(Investment in) bank deposits	(197.43)	-
Net Cash Generated/ (Used) - Investing Activities	275.38	(657.48)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Repayment of Long-term Borrowings	25.29	88.07
Repayment of Lease Liabilities	67.80	(19.05)
Proceeds/(Rapyment)of Short-term Borrowings(Net)	(662.07)	(63.70)
Finance Cost paid	(57.46)	(56.55)
Dividend paid	(165.27)	(148.74)
Net Cash Generated/ (Used) - Financing Activities	(791.71)	(199.97)
Net Increase/ (Decrease) in Cash and Cash Equivalents	521.60	(29.99)
Add : Opening Cash and Cash Equivalents	284.01	486.37
Closing Cash and Cash Equivalents	805.61	456.38

Notes:

- The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
- Figures in bracket represent outflows.
- Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For Titan Biotech Limited


 [Naresh Kumar Singla]
 Managing Director
 DIN-00027448



Place : Delhi
Date : 12.11.2024